AbCellera Investor Presentation Deck slide image

AbCellera Investor Presentation Deck

PIPELINE UPDATE COPYRIGHT © ABCELLERA 17 PROGRAMS Two AbCellera-led programs advancing into IND-enabling studies. MOLECULE ABCL575 ABCL635 TARGET OX40L undisclosed GPCR or ion channel INDICATION atopic dermatitis undisclosed THERAPEUTIC AREA immunology and inflammation metabolic and endocrine conditions POTENTIAL DIFFERENTIATION best in class first in class November 2nd, 2023 POTENTIAL MARKET SIZE $17B by 2032* >$2B * Source: IQVIA
View entire presentation